Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602453 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT06602453 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 67 participants.
The verdict
NCT06602453, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Interventions
- DRUG Placebo
- DRUG GDC-8264
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06602453
The ClinicalTrials.gov registry entry for NCT06602453 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06602453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06602453 about?
NCT06602453 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)". The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two part...
What is the current status of trial NCT06602453?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2025-01-17. Estimated completion is 2026-03-03.
What interventions are being tested in trial NCT06602453?
The interventions under investigation include: Placebo (DRUG), GDC-8264 (DRUG).
Who is sponsoring clinical trial NCT06602453?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.